Journal
VACCINE
Volume 29, Issue 5, Pages 960-968Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.11.050
Keywords
Dengue; DNA vaccines; Clinical trials
Categories
Funding
- work unit Flavivirus Vaccine Research [62787A.870.S.A0014, 62787A.870.S.A0235]
Ask authors/readers for more resources
Candidate dengue DNA vaccine constructs for each dengue serotype were developed by incorporating pre-membrane and envelope genes into a plasmid vector. A Phase 1 clinical trial was performed using the dengue virus serotype-1 (DENV-1) vaccine construct (D1ME(100)). The study was an open-label, dose-escalation, safety and immunogenicity trial involving 22 healthy flavivirus-naive adults assigned to one of two groups. Each group received three intramuscular injections (0, 1, and 5 months) of either a high dose (5.0 mg, n = 12) or a low dose (1.0 mg, n = 10) DNA vaccine using the needle-free Biojector(R) 2000. The most commonly reported solicited signs and symptoms were local mild pain or tenderness (10/22,45%). local mild swelling (6/22, 27%), muscle pain (6/22, 27%) and fatigue (6/22, 27%). Five subjects (41.6%) in the high dose group and none in the low dose group developed detectable anti-dengue neutralizing antibodies. T-cell IFN gamma responses were detected in 50% (4/8) and 83.3% (10/12) of subjects in the low and high dose groups, respectively. The safety profile of the DENV-1 DNA vaccine is acceptable at both doses administered in the study. These results demonstrate a favorable reactogenicity and safety profile of the first in human evaluation of a DENV-1 DNA vaccine. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available